Literature DB >> 22729655

Prevalence and pathogenesis of extended-spectrum beta-lactamase producing Escherichia coli causing urinary tract infection in hospitalized patients.

A Gündoğdu1, Y B Long, M Katouli.   

Abstract

A total of 296 E. coli strains isolated from hospitalized patients with urinary tract infection were included in this study. These strains were tested for their resistance to 22 antimicrobial drugs and the presence of ESBLs genes coding for TEM, SHV, OXA, and CTX-M. We further characterized them for their interaction with a renal cell line (A-498) and a gastrointestinal cell line (Caco-2). Strains were also typed using a combination of RAPD-PCR, PhP-typing and phylogenetic grouping. Only eight strains (2.7 %) were confirmed as ESBLs producers. The most common clonal type contained 35 isolates and only two of them were ESBLs producers and both showed a high degree of adhesion to both cell lines but only one was able to translocate in Caco-2 cells. These strains belonged to phylogenetic group B2, were resistant to nine antibiotics and carried CTX-M-type of ESBL. The remaining six strains belonged to single clones with different phylogenetic groups and ESBL genotypes and were resistant to between 12 and 15 antibiotics. They also showed a high rate of adhesion to A-498 cells (19 ± 2 to 35 ± 3 CFU/cell) and all translocated in this cell line. The rate of adhesion of ESBL-producing strains to Caco-2 cells (11 ± 3.4 CFU/cell) was significantly lower than A-498 cells (26 ± 8 CFU/cell) (p = 0.0002) and only four of them translocated in Caco-2 cells. Our results suggest that the ESBL-producing clones of E. coli have a potential to translocate and cause septicemia in hospitalized patients with UTI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22729655     DOI: 10.1007/s10096-012-1672-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  58 in total

Review 1.  Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs.

Authors:  Betsy Foxman; Patricia Brown
Journal:  Infect Dis Clin North Am       Date:  2003-06       Impact factor: 5.982

Review 2.  Therapeutic challenges of urosepsis.

Authors:  F M E Wagenlehner; A Pilatz; K G Naber; W Weidner
Journal:  Eur J Clin Invest       Date:  2008-10       Impact factor: 4.686

3.  Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended-spectrum beta-lactamases.

Authors:  H Vahaboglu; R Ozturk; H Akbal; S Saribas; O Tansel; F Coşkunkan
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

4.  Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region.

Authors:  Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Sameer Elsayed; Kevin B Laupland
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

5.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.

Authors:  D A Schiappa; M K Hayden; M G Matushek; F N Hashemi; J Sullivan; K Y Smith; D Miyashiro; J P Quinn; R A Weinstein; G M Trenholme
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

6.  Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli.

Authors:  Hanna E Sidjabat; David L Paterson; Zubair A Qureshi; Jennifer M Adams-Haduch; Alexandra O'Keefe; Alvaro Pascual; Jesús Rodríguez-Baño; Yohei Doi
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

7.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

8.  Large-scale population structure of human commensal Escherichia coli isolates.

Authors:  Patricia Escobar-Páramo; Karine Grenet; Arnaud Le Menac'h; Luc Rode; Emmanuelle Salgado; Christine Amorin; Stéphanie Gouriou; Bertrand Picard; Mohamed Chérif Rahimy; Antoine Andremont; Erick Denamur; Raymond Ruimy
Journal:  Appl Environ Microbiol       Date:  2004-09       Impact factor: 4.792

9.  Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes.

Authors:  Johann D D Pitout; Nancy D Hanson; Deirdre L Church; Kevin B Laupland
Journal:  Clin Infect Dis       Date:  2004-05-25       Impact factor: 9.079

10.  Urinary-tract infection and bacteraemia in hospitalized medical patients--a European multicentre prevalence survey on nosocomial infection.

Authors:  O B Jepsen; S O Larsen; J Dankert; F Daschner; P Grönroos; P D Meers; B Nyström; M Rotter; J Sander
Journal:  J Hosp Infect       Date:  1982-09       Impact factor: 3.926

View more
  3 in total

1.  Invasion and translocation of uropathogenic Escherichia coli isolated from urosepsis and patients with community-acquired urinary tract infection.

Authors:  B Owrangi; N Masters; A Kuballa; C O'Dea; T L Vollmerhausen; M Katouli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-16       Impact factor: 3.267

2.  Numerical interpretation of TRS-PCR profiling results for Escherichia coli strains isolated from patients with bacteriuria in Lodz region, Poland.

Authors:  Marta Majchrzak; Anna B Kubiak-Szeligowska; Dariusz Jarych; Pawel Parniewski
Journal:  Mol Biol Rep       Date:  2019-06-25       Impact factor: 2.316

3.  Antibiotic resistance pattern of different Escherichia coli phylogenetic groups isolated from human urinary tract infection and avian colibacillosis.

Authors:  Ali Kazemnia; Malahat Ahmadi; Mahdi Dilmaghani
Journal:  Iran Biomed J       Date:  2014
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.